[U.S. Stocks Movement] Arrivent plunges on October 6: FURVENT trial fails and primary endpoints not met

Arrivent October 6th: Major Decline Analysis

Keywords: FURVENT trial failure, primary endpoint not achieved

On October 6, 2026, ArriVent announced that the FURVENT Phase III trial did not achieve the primary endpoint of progression-free survival as assessed by a blinded independent central review. The median progression-free survival was 11.0 months in the firmonertinib 240mg group, compared to 9.5 months in the control group. The difference was not statistically significant, with a p-value of 0.0654. The company stated it is currently evaluating subsequent development strategies.

(Disclaimer: This content was generated by AI technology by collecting and summarizing public information. It is for reference only and does not constitute investment advice.)